RxDoctor Payments Data

Catherine Spratt Turner, DO

Family Medicine · Newtown, PANPI 1578526380

Payments from drug & device makers

$27,341in general payments, 2019–2025

Across 1,718 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • AbbVie$3K
  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • GSK$1K
  • Amgen$1K
  • plus $15K from 54 others

What the payments were for

  • Food & beverage$27,11499%
  • Education$2271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca166$3,666
AbbVie(2 entities)212$2,822
Novo Nordisk115$1,699
Lilly USA, LLC109$1,614
GSK92$1,330
Amgen(2 entities)75$1,157
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC87$1,150
Boehringer Ingelheim54$1,001
Pfizer100$955
Bayer44$855
Astellas Pharma US Inc42$743
Takeda Pharmaceuticals U.S.A., Inc.50$731
Johnson & Johnson47$726
Merck53$692
Axsome Therapeutics, Inc.27$579
Corium, LLC28$503
Amarin Pharma, Inc.38$503
Esperion Therapeutics, Inc.28$410
Radius Health, Inc.22$349
Teva Pharmaceuticals USA, Inc.27$347
Sumitomo Pharma America, Inc.16$344
Exact Sciences18$338
Novartis21$326
Kowa Pharmaceuticals America, Inc.22$285
Abbott15$272
Almatica Pharma LLC17$268
Lundbeck LLC15$254
Otsuka America Pharmaceutical, Inc.14$248
Neurocrine Biosciences, Inc.11$246
Vanda Pharmaceuticals Inc.14$246
Supernus Pharmaceuticals, Inc.7$240
Ironshore Pharmaceuticals Inc.11$213
Jazz Pharmaceuticals Inc.9$181
Harmony Biosciences LLC5$177
Sunovion Pharmaceuticals Inc.11$169
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)7$154
Ardelyx, Inc.7$144
Neos Therapeutics, LP8$126
Scilex Pharmaceuticals Inc.6$113
Mylan Specialty L.p.6$78
Sanofi-aventis U.S. LLC4$77
Eisai Inc.4$70
Arbor Pharmaceuticals, Inc.5$70
Phathom Pharmaceuticals, Inc.4$64
Shield Therapeutics Inc1$60
Collegium Pharmaceutical, Inc.3$59
Optinose US, Inc.3$48
Verona Pharma, Inc.2$43
Bausch Health US, LLC2$39
Acerus Pharmaceuticals Corporation2$38
Tris Pharma Inc2$38
Impel Pharmaceuticals Inc.2$34
Clarus Therapeutics Inc.2$33
Idorsia Pharmaceuticals US Inc2$32
Adlon Therapeutics L.p.2$28
Intra-sana Laboratories2$27
Seqirus USA Inc1$25
IBSA Pharma Inc.1$25
Linus Health, Inc.1$22
Agile Therapeutics, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,341 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$268,373
Medicare patients
501
Services billed
2,430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide365$437,709
FarxigaDapagliflozin Propanediol266$228,938
JardianceEmpagliflozin220$208,843
OzempicSemaglutide154$162,010
TrulicityDulaglutide116$155,517
EliquisApixaban157$146,551
Trelegy ElliptaFluticasone/Umeclidin/Vilanter153$127,374
IngrezzaValbenazine Tosylate13$105,718
HumiraAdalimumab13$84,226
JanuviaSitagliptin Phosphate43$46,328
XifaxanRifaximin16$42,585
VraylarCariprazine Hcl26$36,538
AristadaAripiprazole Lauroxil12$34,766
Breztri AerosphereBudesonide/Glycopyr/Formoterol55$33,462
Breo ElliptaFluticasone/Vilanterol49$30,033

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,614$593,226481 claims
AstraZenecaFarxiga, Breztri Aerosphere$3,666$262,400321 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta$1,001$228,967252 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$1,330$165,520226 claims
Novo NordiskOzempic$1,699$162,010154 claims
AbbVieHumira, Vraylar, Linzess, Synthroid$2,822$156,483215 claims
PfizerEliquis$955$146,551157 claims
Neurocrine Biosciences, Inc.Ingrezza$246$105,71813 claims
MerckJanuvia$692$46,32843 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,150$42,58516 claims
BayerKerendia$855$29,32528 claims
AmgenProlia$1,157$27,13816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Newtown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →